Business Context and Reporting Period
CareDx, Inc. filed this Form 8-K on January 17, 2017, to disclose the entry into a Material Definitive Agreement. On this date, CareDx Pty Ltd, a wholly owned subsidiary of CareDx, Inc., entered into a Business Sale Agreement (BSA) with Conexio Genomics Pty Ltd, an affiliate of Illumina, Inc.
Key Financial Metrics and Transaction Terms
The filing details a specific asset acquisition rather than standard periodic financial performance metrics. The transaction involves the purchase of assets related to Sequencing Based HLA Typing (SBT) products. Key financial terms include:
- Finished Goods Payment: Up to $232,792 payable on or before July 1, 2017.
- Unfinished Inventory Payment: $156,159 payable upon the earlier of December 31, 2017, or 30 days after the first productive use of the inventory.
- Revenue Royalties: Quarterly payments equal to 20% of gross revenue from products using the acquired assets, capped at an aggregate total of $735,000.
- Liabilities Assumed: Product warranty claims up to a maximum of $35,000 and obligations under the Conexio facility lease.
The filing text does not provide clear values for CareDx, Inc.'s overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Transaction Structure
The primary material change is the strategic acquisition of manufacturing and intellectual property assets from Conexio. The transaction structure includes:
- Asset Transfer: Purchase of SBT product manufacturing and selling assets.
- Lease Assumption: CareDx Pty will assume the lease for Conexio facilities in Freemantle, Western Australia, subject to novation or assignment.
- Licensing and Support: A License Agreement for software, technology, and trademarks, and a Secondment Agreement with Illumina Australia Pty Ltd to provide an employee for 12 months to assist with the transfer of operations.
Outlook, Risks, and Contingencies
Closing Conditions: The acquisition is expected to close on January 21, 2017, or shortly thereafter, subject to conditions including the successful assignment of the facility lease.
Risks and Contingencies:
- Indemnification: Conexio has agreed to indemnify CareDx Pty against losses related to breaches of representations and warranties, subject to customary limitations.
- Confidentiality: Certain terms of the BSA are omitted from this report and will be filed with a confidential treatment request in future 10-K or 10-Q filings.
- Operational Transition: Reliance on the Secondment Agreement for the transfer of manufacturing expertise.
Investor Verification Checklist
- Verify the successful closing of the acquisition and the assignment of the Freemantle facility lease.
- Monitor the execution of the License Agreement and the 12-month Secondment Agreement with Illumina.
- Review the full text of the BSA in the upcoming Form 10-K or Form 10-Q to understand omitted terms and confidential treatment requests.
- Track the revenue generation from the acquired assets to determine the timeline for reaching the $735,000 royalty cap.